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Everythingmust be taken into account. If the fact will not fit the theory—let
the theory go.
—Agatha Christie, The Mysterious Affair at Styles
Brugada syndrome (BrS) has been named after the description of the
disease made by the Brugada brothers in 1992.1 BrS is clinically charac-
terized by arrhythmic events, in particular ventricular fibrillation, result-
ing in syncope and sudden cardiac arrestmainly inmiddle-agedmen. The
ECG shows a peculiar down-sloping elevation of the ST segment in the
right pre-cordial ECG leads with inversion of T-waves.2 Since 1998, a
genetic component to BrS has been demonstrated.3 Over the past
years, at least 20 genes have been proposed either to cause BrS or to
be BrS-susceptibility genes.4
For several years, SCN5A, which encodes the ‘cardiac sodiumchannel’
Nav1.5, was presented as a gene ‘causing’ BrS in 20% of the patients;
however, this concept had to be revised due to recent findings. First,
in some families where the probands were found to carry SCN5A rare
variants, other familymembersdiagnosedwithBrSdidnot carry the sup-
posedly pathogenic variant.5,6 Second, a recent genome-wide associ-
ation study (GWAS) led to the concept that BrS could no longer be
considered a monogenic disease and it suggested a key role for the
three genes: SCN10A, SCN5A, and HEY2.7 Patients who accumulated
more than four of the risk alleles in these genes had an odds ratio of
.20 to have BrS. The two genes SCN5A and SCN10A, which encode
two different voltage-gated sodium channels, were also implicated in
other GWAS studies8 in physiological cardiac conduction, assessed as
ECGparameters. These findingsmotivated several groups to investigate
the, thus far, unknown role of the SCN10A gene product, the sodium
channel Nav1.8, in cardiac electrical activity as this channel was only
thought to be important in the sensory nervous system.
As it sometimes happens in science, this has led to controversial
results. The first unresolved question is the location of expression of
Nav1.8 in cardiac tissues. Two hypotheses are currently debated. On
the one hand, expression of Nav1.8 is proposed by one research
group to be specific to intracardiac neurons,9 while on the other hand,
expression in cardiac myocytes of the myocardium and of the conduc-
tionpathwaywas suggestedbyanother group.10The secondpointof dis-
agreement is the role of genetic variants that were found in the gene
SCN10A in patients with cardiac arrhythmias, in particular BrS. Upon in-
vestigation of a population of 150 BrS probands and family members, a
recent study by Hu et al.11 came to the conclusion that SCN10A
genetic variants may cause BrS in 16.7% of these probands, thus
putting SCN10A as a major susceptibility gene of BrS.
In the current issue of Cardiovascular Research, Dr E.R. Behr presents a
multi-centre collaborative study,12 involving 156 SCN5Amutation nega-
tive BrS probands where 7 candidate genes, including SCN10A, were
sequenced. Contrary to the previous study by Hu et al.,11 while most
of the rare genetic variants were found in SCN10A, no statistical associ-
ationwith these SCN10Avariants andBrSwasobserved.However,many
of these variants showed functional alterations, such as reduction in
Nav1.8-mediated sodium current when studied by patch clamping.
Behr et al.12 did not investigate the functional consequences of the
co-expression of the Nav1.8 with the Nav1.5 channel in the same cells
as done by Hu et al.11 Their rationale not to study it is based on the evi-
dence that these two channels are not co-expressed in cardiomyo-
cytes.9 This question of co-expression still remains unsolved, but one
can nevertheless note that proteomic studies13 performed using
mouse cardiac tissue only revealed significant amounts of Nav1.5 and
Nav1.4 peptides and none from Nav1.8. These observations by Behr
et al. suggest that, while these rare Nav1.8 variants and their functional
effects are consistent with the observed role of this channel in cardiac
conduction, they are not directly involved in the pathogenesis of BrS.
The authors of the present study thus concluded that ‘rare variation in
SCN10, particularly in SCN5A mutation negative cases, is unlikely to
cause BrS’. Behr et al. discuss the possible origins of this discrepancy
and propose that their studied BrS population is more focused
(enriched), and that a more stringent ‘mutation’ definition had been
used. They also mention that by looking at larger control variant data-
bases, only 2% of the SCN10A variants reported by Hu et al.11 should
be classified as ‘rare’. Here, one should also mention the recent study
by Le Scouarnec et al.4 from the Institut du Thorax in Nantes, where
the burden of rare coding variants in 20 BrS genes was estimated.
Using a ‘burden test’ for the exonic sequences of these genes from
167 BrS probands, a significant enrichment in rare variants [with a
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definition of the minor allele frequency (MAF) ,0.1% in an ethnically
matched control population] was only observed for SCN5A, but not
for SCN10A. These results are in line with the ones of the current
study of Behr et al. in this issue of Cardiovascular Research. Importantly,
these authors discuss that if Hu et al.11would also have used such a strin-
gent rare variant definition of MAF,0.1% (instead of ,0.5%), the pro-
portion of SCN10A carriers in BrS patients would have fallen to 7.3%
instead of 16.7%. Thus, these two studies by Behr et al.12 and Le Scouar-
nec et al.4 do not support the concept that SCN10A is a major suscepti-
bility gene in BrS and propose plausiblemethodological explanations for
the discrepant results.
There is no doubt that controversies are intrinsic to the scientific
process; this is most likely a positive thing! However, in this case one
has to be extremely careful, since these findings may have important
consequences, as they may be used for guiding the work-up of patients
with BrS and their family members. It is therefore important to replicate
similar studies in larger populations (and similarly sized control popula-
tions) as well as from other ethnic backgrounds, and use a cautious def-
inition of ‘rare variant’ as proposed in study4 to sort through the role of
SCN10A in BrS and other genetic cardiac arrhythmias.
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